Question 1

What is the indication of Alecensaro?

Accepted Answer

Alecensaro (alectinib) is specifically approved for use as a single-agent therapy for treating individuals diagnosed with ALK-positive, NSCLC (non-small cell lung cancer) that is either locally advanced and not suitable for curative treatment or metastatic. This medication is particularly prescribed for patients who have either not responded to or cannot tolerate crizotinib, providing an alternative for those needing ongoing management of their lung cancer.

Question 2

How long can you take Alecensaro?

Accepted Answer

This medication is generally continued until the cancer shows signs of progression or the patient experiences side effects that are too severe to manage. This ensures that the medication is used as long as it is effective and tolerable for the patient.

Question 3

Is ALK curable?

Accepted Answer

ALK-positive lung cancer is not considered curable but can be effectively managed with targeted medications like Alecensaro. This medication specifically targets the abnormal protein produced by the ALK gene mutation, which is often responsible for the development of this type of cancer. By focusing on this mutation, Alecensaro can help control the growth & spread of cancer cells, leading to prolonged survival and a better quality of life for patients.

Question 4

Does alectinib cause constipation?

Accepted Answer

Yes, alectinib can cause constipation as a side effect. While effective in its therapeutic role, alectinib can disrupt normal gastrointestinal function, leading to constipation, among other potential side effects. If you’re experiencing constipation while on alectinib, it’s important to discuss this with your healthcare provider, as they can recommend appropriate measures to manage this condition, such as dietary adjustments, hydration, or possibly medication to alleviate the discomfort.

Question 5

Is Alecensaro better than Xalkori?

Accepted Answer

Yes. Alecensaro is frequently favored over Xalkori as a first-line treatment for several reasons, most notably its higher efficacy in clinical outcomes and its reduced incidence of central nervous system side effects. This preference is grounded in comparative studies and clinical trials where Alecensaro demonstrated superior effectiveness in managing symptoms and progression of disease conditions that both medications aim to treat.

Question 6

Does alectinib shrink tumors?

Accepted Answer

Yes, alectinib is used to treat patients with tumors that are caused by changes in the ALK gene and who have not responded to the ALK inhibitor crizotinib, also known as Xalkori. In two early-stage clinical trials, alectinib has effectively reduced the size of tumors in these patients, showing its potential as a useful treatment for those who do not benefit from crizotinib.

Question 7

Does Alecensaro cause hair loss?

Accepted Answer

No, hair loss is not listed as a side effect of Alecensaro (alectinib), based on data from clinical trials. If you start experiencing hair loss after beginning this medication, it’s important to consult your doctor.